Comparison · NCT01785602-sae
QAW039 vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. QAW039 vs Placebo: serious adverse events. Trial comparisons, record NCT01785602-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01785602-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0132 | 0.00233 | 0.0708 | wilson | |
| Risk in group 2 | 0.148 | 0.0592 | 0.325 | wilson | |
| Risk difference, group 1 minus group 2 | -0.135 | -0.312 | -0.0289 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.0888 | 0.0104 | 0.76 | log | |
| Odds ratio, group 1 over group 2 | 0.0767 | 0.00816 | 0.721 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on QAW039 than on Placebo | 7.41 | 3.21 | 34.5 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | QAW039 | Participants received QAW039 450 mg daily by mouth. | 1 | 76 | EG000 |
| Group 2 | Placebo | Participants received matching placebo to QAW039. | 4 | 27 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Serious adverse events were collected from day 1 until 4 weeks after end of study (week 20)
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.
- NCT number
- NCT01785602
- Phases
- PHASE2
- Conditions
- Atopic Dermatitis
- Interventions
- QAW039, Placebo
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2015-12-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01785602?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01785602-sae